What the research found
Researchers tested whether a oral supplement containing heat-inactivated Lactiplantibacillus plantarum (a probiotic-derived postbiotic) plus micronutrients and plant extracts could shift weight and metabolic markers in 80 adults with overweight or obesity over 8 weeks. The treatment group lost about 2.6 kg on average, while the placebo group gained slightly. The more striking finding was that circulating active GLP-1—the hormone that regulates appetite and blood sugar—roughly doubled in the treatment arm and rose more than in controls. Within the treated group, stool levels of the specific bacterial strain correlated with blood GLP-1 levels, suggesting the postbiotic was mechanistically linked to the hormone response.
Beyond weight, participants receiving the active treatment reported sharper drops in food cravings and depressive symptoms. Safety markers remained normal, and gastrointestinal side effects were actually less common in the treatment group than placebo.
Why it matters for you
If you're tracking GLP-1 as a biomarker—whether considering exogenous GLP-1 peptides or optimising endogenous production—this hints at an oral alternative that doesn't require injection. An 8-week lift in fasting GLP-1 of that magnitude could reduce appetite noise and support a calorie deficit without pharmaceutical intervention, which appeals to people wanting to work with their biology rather than replace it.
The reduction in food cravings is the practical payoff: it's much easier to maintain a training protocol and hit macros when your brain isn't fighting constant hunger signals. The concurrent drop in depressive symptoms is notable too—mood and metabolic health are entangled, and weight loss alone doesn't always shift depression.
That said, this is a short intervention in a small, remote-only cohort. Whether the effect sustains beyond 8 weeks, whether it works in leaner individuals, and whether the response is large enough to rival actual GLP-1 therapy remain open questions.
Caveats
- Short duration: 8 weeks is insufficient to assess whether weight loss persists or whether tolerance to the postbiotic develops
- Small and self-selected sample: 80 participants in a fully remote setting may not reflect real-world compliance or broader populations
- Composite formula: The supplement contains six active ingredients (postbiotic, vitamins, chromium, plant extracts), so the relative contribution of each is unclear
- No active comparator: No head-to-head comparison with existing weight-loss interventions or standard GLP-1 dosing
- Preliminary mechanistic data: The correlation between stool L. plantarum and GLP-1 is suggestive but does not prove causation; intestinal barrier permeability and other factors weren't measured
- Industry involvement likely: The trial registered as NCT06911073; funding source and author conflicts should be checked in the full paper